Humacyte (HUMA) investor relations material

Executive summary

• Achieved continued execution of the U.S. commercial launch of Symvess, with expansion into international markets and strong interest from military and global partners.

• Secured 27 VAC approvals and 27 hospitals ordering Symvess, with most placing reorders; 43 additional VAC committees are reviewing.

• Received a $1.475 million purchase commitment for clinical evaluation in Saudi Arabia and submitted a marketing authorization application in Israel.

• U.S. Department of Defense allocated funding for procurement of bioengineered blood vessels.

• Anticipates top-line interim results from V012 Phase 3 hemodialysis study in Q2 2026, supporting a planned BLA filing in the second half of 2026.

Financial highlights

• Q4 2025 product sales were $0.4 million; full year 2025 product sales reached $1.4 million, with total revenue of $2.0 million including research collaborations.

• Cost of goods sold for 2025 was $9.7 million, including an $8.9 million inventory reserve due to limited sales history.

• Research and development expenses decreased to $69.3 million for 2025 from $88.6 million in 2024, reflecting transition to commercial operations.

• Selling, general, and administrative expenses rose to $31.2 million in 2025, up from $25.8 million in 2024, driven by commercial launch activities.

• Net loss for 2025 was $40.8 million, a significant improvement from $148.7 million in 2024, primarily due to increased other net income and lower operating expenses.

• Cash and cash equivalents stood at $50.5 million at year-end, with an additional $23 million raised post-year-end.

Outlook and guidance

• Anticipates gradual sales growth for Symvess, with continued expansion in U.S. trauma centers and international markets.

• Interim results from the V012 phase III trial in women for dialysis access expected by early June 2026; supplemental BLA submission planned for the second half of 2026.

• First-in-human study for coronary tissue engineered vessel (CTEV) in coronary artery bypass grafting targeted for the second half of 2026, pending FDA clearance.

• DoD procurement funding expected to be spent in calendar 2026, with potential for additional military contracts in future years.